[{"Assets_0_Q3_USD":443858000.0,"CommonStockSharesOutstanding_0_Q3_shares":98948935.0,"NetCashProvidedByUsedInOperatingActivities_1_Q3_USD":14907000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":19658000.0,"NetIncomeLoss_1_Q3_USD":1930000.0,"NetIncomeLoss_3_Q3_USD":-11490000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":98485519.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":96551041.0,"StockholdersEquity_0_Q3_USD":190365000.0,"EarningsPerShareBasic_1_Q3_USD":0.02,"EarningsPerShareBasic_3_Q3_USD":-0.12,"Ticker":"NVCR","CIK":"1645113","name":"NOVOCURE LTD","OfficialName":"NovoCure Limited Ordinary Shares","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"8608333440.0","Country":"Jersey","Sector":"Health Care","Industry":"Biotechnology: Electromedical & Electrotherapeutic Apparatus","Market":"NASDAQ","SP500":"nan","filed":"20191031"}]